Sandbox Reserved 972
From Proteopedia
(Difference between revisions)
Line 20: | Line 20: | ||
==Bradykinin== | ==Bradykinin== | ||
- | <scene name='60/604491/Bradykinin/1'>Bradykinin</scene> is a short lived vasoactive nonapeptide mediator of the family of kinins. It's secreted in response to an inflammatory envent and serves as a mediator of pain, inflammation and vasodilatation. It is secreted by the enzymatic action of kallikreins on kininogen precursors<ref> | + | <scene name='60/604491/Bradykinin/1'>Bradykinin</scene> is a short lived vasoactive nonapeptide mediator of the family of kinins. It's secreted in response to an inflammatory envent and serves as a mediator of pain, inflammation and vasodilatation. It is secreted by the enzymatic action of kallikreins on kininogen precursors<ref>PMID: PMC2658795</ref>. Kallidin is a produt of the enzymatic action of kallikrein to kininogens. Then Kallidin is transformed into bradykinin |
Today, we know that kinins can be degraded by IDE. | Today, we know that kinins can be degraded by IDE. | ||
Revision as of 22:34, 9 January 2015
This Sandbox is Reserved from 15/11/2014, through 15/05/2015 for use in the course "Biomolecule" taught by Bruno Kieffer at the Strasbourg University. This reservation includes Sandbox Reserved 951 through Sandbox Reserved 975. |
To get started:
More help: Help:Editing |
|
References
- ↑ Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-Fery M, Sun CY, Meredith SC, Sisodia SS, Leissring MA, Tang WJ. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J Biol Chem. 2007 Aug 31;282(35):25453-63. Epub 2007 Jul 5. PMID:17613531 doi:10.1074/jbc.M701590200
- ↑ Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature. 2006 Oct 19;443(7113):870-4. Epub 2006 Oct 11. PMID:17051221 doi:10.1038/nature05143
- ↑ PMID: PMC2658795
- ↑ Song ES, Juliano MA, Juliano L, Hersh LB. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development. J Biol Chem. 2003 Dec 12;278(50):49789-94. Epub 2003 Oct 2. PMID:14527953 doi:http://dx.doi.org/10.1074/jbc.M308983200
- ↑ Malito E, Ralat LA, Manolopoulou M, Tsay JL, Wadlington NL, Tang WJ. Molecular Bases for the Recognition of Short Peptide Substrates and Cysteine-Directed Modifications of Human Insulin-Degrading Enzyme. Biochemistry. 2008 Nov 6. PMID:18986166 doi:10.1021/bi801192h
- ↑ Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-Fery M, Sun CY, Meredith SC, Sisodia SS, Leissring MA, Tang WJ. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J Biol Chem. 2007 Aug 31;282(35):25453-63. Epub 2007 Jul 5. PMID:17613531 doi:10.1074/jbc.M701590200